Ongoing Clinical Trials

• A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. Role: Principal Investigator. Status: Enrolling patients.

• A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer. Role: Principal Investigator. Status: Enrolling patients.

• Prospective Phase 2/3 Multi-Center Study of 18 F-DCFP yL PET/CT Imaging in Patients with Prostate Cancer: Examination of Diagnostic Accuracy (OSPREY). Role: Principal Investigator. Status: Enrolling patients.

• A Phase II trial of Nivolumab plus Ipilimumab in men with metastatic Castration-Resistant Prostate Cancer (mCRPC). Role: Principal Investigator. Status: Enrolling patients.

• A Phase Ib investigator-initiated trial to determine safety profile and feasibility for the combination of rucaparib and nivolumab in metastatic, castrate-resistant prostate cancer and endometrial cancer patients. Role: Designer and Principal Investigator. Status: lRB approved.

• A Phase Ib investigator-initiated trial to determine safety profile and feasibility for the combination of GSK2636771 (PI3K β-selective inhibitor) plus pembrolizumab in metastatic, PTEN-deficient castrate-resistant prostate cancer and endometrial cancer patients. Role: Designer and Principal Investigator. Status: Protocol in preparation.